Anti-Human IL12+IL23 Recombinant Antibody (Briakinumab) (CAT#: TAB-103)

Recombinant monoclonal antibody to IL12+IL23. Briakinumab (ABT-874) is a human monoclonal antibody for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe. Like ustekinumab, the antibody targets the interleukins 12 and 23.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Datasheet
  • MSDS
  • COA
IF

Figure 1 Differential sorting of briakinumab and ustekinumab in FcRn-positive sorting endosomes.

Figure 1 Differential sorting of briakinumab and ustekinumab in FcRn-positive sorting endosomes.

HUVECs were incubated together with 200 μg/mL both briakinumab (labeled with AlexaFluor594) and ustekinumab (labeled with AlexaFluor488) for 20 min at 37 °C, pH 7.3, followed by 20 min chase. At the end of the experiment, cells were fixed and counterstained with a monoclonal antibody directed against FcRn (DVN22) (44) detected by secondary antibodies labeled with AlexaFluor647.

Schoch, A., Kettenberger, H., Mundigl, O., Winter, G., Engert, J., Heinrich, J., & Emrich, T. (2015). Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proceedings of the National Academy of Sciences, 112(19), 5997-6002.

PK

Figure 2 Correlation between in vivo PK parameters and FcRn column elution pHs.

Figure 2 Correlation between in vivo PK parameters and FcRn column elution pHs.

Antibodies were administered as a single i.v. bolus injection of 10 mg/kg to six animals per group. Data points represent the mean ± SD. (A) Blood level curves of briakinumab (orange), ustekinumab (green), mAb 8 (purple), and mAb 9 (blue). (B) Correlation between the terminal half-lives with the FcRn column elution pH.

Schoch, A., Kettenberger, H., Mundigl, O., Winter, G., Engert, J., Heinrich, J., & Emrich, T. (2015). Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proceedings of the National Academy of Sciences, 112(19), 5997-6002.

PK

Figure 3 Pharmacokinetic analysis.

Figure 3 Pharmacokinetic analysis.

(A) Data reproduction of pharmacokinetic study in hFcRn transgenic mice from Schoch et. al. 17 Only early time points are displayed to highlight initial distribution kinetics of ustekinumab (gray, dashed line) versus briakinumab (black, solid line). (B) Pharmacokinetic study in FcRn KO mice. Each time point represents the average serum concentration for the 3 mice, and these averages were fit for each antibody using a 2 phase non-compartmental decay curve.

Kelly, R. L., Yu, Y., Sun, T., Caffry, I., Lynaugh, H., Brown, M.,... & Wittrup, K. D. (2016, October). Target-independent variable region mediated effects on antibody clearance can be FcRn independent. In MAbs (Vol. 8, No. 7, pp. 1269-1275). Taylor & Francis.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Human
  • Derivation
  • Human
  • Type
  • IgG1 - lambda
  • Specificity
  • Tested positive against native human antigen.
  • Species Reactivity
  • Human
  • Applications
  • WB, FC, IP, ELISA, Neut, FuncS, IF, PK
  • CAS
  • 339308-60-0
  • Generic Name
  • Briakinumab
  • ATC Code
  • L04AC09
  • UNII
  • 978I8M0P8X
  • MW
  • 146.5 kDa
  • Related Disease
  • Crohn's disease (CD)

Product Property

  • Purity
  • >95.0% as determined by analysis by RP-HPLC.
  • Storage
  • Store at -20°C. Avoid multiple freeze/thaw cycles.

Applications

  • Application Notes
  • The IL12+IL23 antibody has been reported in applications of WB, FC, IP, ELISA, Neut, FuncS, IF, PK.

Target

  • Alternative Names
  • Briakinumab;339308-60-0;ABT-874;J695;BSF 415977;LU 415977;WAY-165772;A-796874.0;ABT-874;IL12B;interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40);NKSF2;interleukin-12 subunit beta;CLMF;CLMF2;cytotoxic

Related Resources

  • Biosimilar Overview
Please refer to Briakinumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Briakinumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Briakinumab"

Afuco™ Anti-IL12+IL23 ADCC Recombinant Antibody (Briakinumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to IL12+IL23. Briakinumab (ABT-874) is a human monoclonal antibody for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe. Like ustekinumab, the antibody targets the interleukins 12 and 23.

See other products for "IL12+IL23"

Single-domain Antibody

CAT Product Name Application Type
NAB-1410-VHH Recombinant Anti-Human IL12+IL23 VHH Single Domain Antibody WB, IP, ChiP, Neut, ELISA Llama VHH

Human Antibody

CAT Product Name Application Type
TAB-063 Anti-Human IL12+IL23 Recombinant Antibody (Ustekinumab) WB, FuncS, IF, Neut, ELISA, FC, IP IgG1 - kappa

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-063 Afuco™ Anti-IL12+IL23 ADCC Recombinant Antibody (Ustekinumab), ADCC Enhanced FuncS, IF, Neut, ELISA, FC ADCC enhanced antibody
AFC-TAB-103 Afuco™ Anti-IL12+IL23 ADCC Recombinant Antibody (Briakinumab), ADCC Enhanced FC, IP, ELISA, Neut, FuncS ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-103. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare